<DOC>
	<DOC>NCT01615393</DOC>
	<brief_summary>This prospective, randomized, single-blind, cross-over study will compare the bioavailability of Copegus (ribavirin) administered as tablets and ribavirin administered as capsules in healthy volunteers. Volunteers will be randomized to receive a single dose of 400 mg of ribavirin either as a capsule or as tablets; after a washout phase volunteers will be crossed-over to the other treatment. The anticipated time on study treatment is 10 days.</brief_summary>
	<brief_title>A Study to Compare the Bioavailability of Copegus and VilonaÂ® in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Adult healthy volunteers, 18 to 55 years of age Clinically healthy as confirmed by medical history, physical examination, electrocardiogram, thorax teleradiography and routine clinical laboratory measurements Body mass index between 18 and 28 kg/m2 Negative testing for drugs of abuse History or presence of any clinically significant condition that might interfere with the pharmacokinetics of the study drugs Volunteers require comedications during the study Exposure to agents known as inducers or inhibitors of hepatic enzymatic system within 30 days prior to study start Having taken any medication with a clearance period of over seven halflife before study start Hospitalization or significant illness 30 days before study start Having received a investigational drug within 90 days prior to study start</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>